EA034854B1 - Анти-il-17-антитела, способ их получения и способ применения - Google Patents
Анти-il-17-антитела, способ их получения и способ применения Download PDFInfo
- Publication number
- EA034854B1 EA034854B1 EA201600276A EA201600276A EA034854B1 EA 034854 B1 EA034854 B1 EA 034854B1 EA 201600276 A EA201600276 A EA 201600276A EA 201600276 A EA201600276 A EA 201600276A EA 034854 B1 EA034854 B1 EA 034854B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- syndrome
- amino acid
- chronic
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 94
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 80
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 80
- 239000012634 fragment Substances 0.000 claims abstract description 45
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 230000027455 binding Effects 0.000 claims abstract description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 39
- 208000035475 disorder Diseases 0.000 claims abstract description 32
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims abstract description 28
- 230000001363 autoimmune Effects 0.000 claims abstract description 21
- 238000006467 substitution reaction Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 208000011580 syndromic disease Diseases 0.000 claims description 47
- 208000019693 Lung disease Diseases 0.000 claims description 31
- 230000001154 acute effect Effects 0.000 claims description 26
- 230000001684 chronic effect Effects 0.000 claims description 25
- 230000002757 inflammatory effect Effects 0.000 claims description 23
- 206010020751 Hypersensitivity Diseases 0.000 claims description 22
- 208000006673 asthma Diseases 0.000 claims description 22
- 208000006454 hepatitis Diseases 0.000 claims description 21
- 231100000283 hepatitis Toxicity 0.000 claims description 21
- 210000000056 organ Anatomy 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 18
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 17
- 206010052779 Transplant rejections Diseases 0.000 claims description 17
- 238000002054 transplantation Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 102000053162 human IL17A Human genes 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 201000004624 Dermatitis Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 208000037157 Azotemia Diseases 0.000 claims description 12
- 230000002093 peripheral effect Effects 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 208000009852 uremia Diseases 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 11
- 208000036487 Arthropathies Diseases 0.000 claims description 11
- 208000012659 Joint disease Diseases 0.000 claims description 11
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 11
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 11
- 230000007850 degeneration Effects 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 11
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 10
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 10
- 206010012442 Dermatitis contact Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 208000007475 hemolytic anemia Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 210000003491 skin Anatomy 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 9
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 230000007815 allergy Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 208000028867 ischemia Diseases 0.000 claims description 9
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 8
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 8
- 208000018631 connective tissue disease Diseases 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 201000002481 Myositis Diseases 0.000 claims description 7
- 208000025584 Pericardial disease Diseases 0.000 claims description 7
- 206010036105 Polyneuropathy Diseases 0.000 claims description 7
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 7
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 7
- 206010061372 Streptococcal infection Diseases 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000016192 Demyelinating disease Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- 208000016604 Lyme disease Diseases 0.000 claims description 6
- 208000019430 Motor disease Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 6
- 206010029240 Neuritis Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 6
- 208000003455 anaphylaxis Diseases 0.000 claims description 6
- 206010003549 asthenia Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 206010014665 endocarditis Diseases 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 230000003176 fibrotic effect Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010028417 myasthenia gravis Diseases 0.000 claims description 6
- 201000005737 orchitis Diseases 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 230000002028 premature Effects 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 6
- 201000004595 synovitis Diseases 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 206010043207 temporal arteritis Diseases 0.000 claims description 6
- 208000009174 transverse myelitis Diseases 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 5
- 208000015879 Cerebellar disease Diseases 0.000 claims description 5
- 206010015150 Erythema Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 5
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 208000002774 Paraproteinemias Diseases 0.000 claims description 5
- 206010034277 Pemphigoid Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 201000008298 histiocytosis Diseases 0.000 claims description 5
- 208000036260 idiopathic disease Diseases 0.000 claims description 5
- 201000004614 iritis Diseases 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 230000002611 ovarian Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 208000002574 reactive arthritis Diseases 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 201000003068 rheumatic fever Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 201000006306 Cor pulmonale Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 4
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 208000001871 Tachycardia Diseases 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 4
- 231100000360 alopecia Toxicity 0.000 claims description 4
- 208000004631 alopecia areata Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 208000037849 arterial hypertension Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000008033 biological extinction Effects 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 206010014801 endophthalmitis Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 230000003394 haemopoietic effect Effects 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000000366 juvenile effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000019629 polyneuritis Diseases 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 230000006794 tachycardia Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 208000023769 AA amyloidosis Diseases 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 206010001889 Alveolitis Diseases 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 3
- 206010002961 Aplasia Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 3
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 3
- 206010003267 Arthritis reactive Diseases 0.000 claims description 3
- 208000006740 Aseptic Meningitis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 3
- 206010003662 Atrial flutter Diseases 0.000 claims description 3
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 3
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 3
- 206010008748 Chorea Diseases 0.000 claims description 3
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010011703 Cyanosis Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010011844 Dacryocystitis Diseases 0.000 claims description 3
- 206010012310 Dengue fever Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010012978 Diffuse vasculitis Diseases 0.000 claims description 3
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 3
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 102000013138 Drug Receptors Human genes 0.000 claims description 3
- 108010065556 Drug Receptors Proteins 0.000 claims description 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 201000000628 Gas Gangrene Diseases 0.000 claims description 3
- 206010018498 Goitre Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000031856 Haemosiderosis Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 3
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 206010022941 Iridocyclitis Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 3
- 208000004023 Legionellosis Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims description 3
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 3
- 206010058858 Meningococcal bacteraemia Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims description 3
- 208000034486 Multi-organ failure Diseases 0.000 claims description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
- 241000186367 Mycobacterium avium Species 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010031149 Osteitis Diseases 0.000 claims description 3
- 208000003076 Osteolysis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010033165 Ovarian failure Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 241000233872 Pneumocystis carinii Species 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 3
- 206010067953 Radiation fibrosis Diseases 0.000 claims description 3
- 208000005587 Refsum Disease Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 206010038546 Renal vasculitis Diseases 0.000 claims description 3
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 206010039811 Secondary amyloidosis Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 208000009714 Severe Dengue Diseases 0.000 claims description 3
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 3
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 3
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 241000223996 Toxoplasma Species 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 3
- 206010046996 Varicose vein Diseases 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 208000018254 acute transverse myelitis Diseases 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 208000030597 adult Refsum disease Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 201000004612 anterior uveitis Diseases 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 206010002895 aortic dissection Diseases 0.000 claims description 3
- 208000021328 arterial occlusion Diseases 0.000 claims description 3
- 230000003143 atherosclerotic effect Effects 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 208000018300 basal ganglia disease Diseases 0.000 claims description 3
- 208000018339 bone inflammation disease Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 210000001638 cerebellum Anatomy 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000000739 chaotic effect Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000002594 corticospinal effect Effects 0.000 claims description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims description 3
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 208000001606 epiglottitis Diseases 0.000 claims description 3
- 201000011384 erythromelalgia Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000010934 exostosis Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 201000003872 goiter Diseases 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
- 201000010930 hyperostosis Diseases 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 230000028709 inflammatory response Effects 0.000 claims description 3
- 230000005865 ionizing radiation Effects 0.000 claims description 3
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims description 3
- 210000001821 langerhans cell Anatomy 0.000 claims description 3
- 201000002364 leukopenia Diseases 0.000 claims description 3
- 231100001022 leukopenia Toxicity 0.000 claims description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 208000022089 meningococcemia Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 208000009928 nephrosis Diseases 0.000 claims description 3
- 231100001027 nephrosis Toxicity 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 3
- 231100000539 ovarian failure Toxicity 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 230000001314 paroxysmal effect Effects 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 230000007824 polyneuropathy Effects 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 230000000552 rheumatic effect Effects 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 201000001223 septic arthritis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 206010042772 syncope Diseases 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 208000027185 varicose disease Diseases 0.000 claims description 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 claims description 2
- 206010003671 Atrioventricular Block Diseases 0.000 claims description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 2
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims description 2
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 2
- 241000832848 Dromas Species 0.000 claims description 2
- 208000007984 Female Infertility Diseases 0.000 claims description 2
- 206010058872 Fungal sepsis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 206010021928 Infertility female Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 206010024715 Liver transplant rejection Diseases 0.000 claims description 2
- 208000007466 Male Infertility Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000012287 Prolapse Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010038915 Retinitis viral Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 210000000709 aorta Anatomy 0.000 claims description 2
- 210000000702 aorta abdominal Anatomy 0.000 claims description 2
- 208000001974 autoimmune enteropathy Diseases 0.000 claims description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims description 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 210000000748 cardiovascular system Anatomy 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 231100000359 cholestasis Toxicity 0.000 claims description 2
- 230000007870 cholestasis Effects 0.000 claims description 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims description 2
- 230000001660 hyperkinetic effect Effects 0.000 claims description 2
- 230000003483 hypokinetic effect Effects 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000002502 lymphedema Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims description 2
- 230000000849 parathyroid Effects 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- 238000007879 vasectomy Methods 0.000 claims description 2
- 208000020854 vein disease Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims 11
- 230000007574 infarction Effects 0.000 claims 11
- 230000000747 cardiac effect Effects 0.000 claims 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- 230000008359 toxicosis Effects 0.000 claims 7
- 208000026872 Addison Disease Diseases 0.000 claims 6
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 5
- 206010048396 Bone marrow transplant rejection Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000003782 Raynaud disease Diseases 0.000 claims 4
- 208000034189 Sclerosis Diseases 0.000 claims 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 4
- 208000017972 multifocal atrial tachycardia Diseases 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- 206010053172 Fatal outcomes Diseases 0.000 claims 3
- 241000721454 Pemphigus Species 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 241000712431 Influenza A virus Species 0.000 claims 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 2
- 206010024648 Livedo reticularis Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 2
- 206010053869 POEMS syndrome Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010035742 Pneumonitis Diseases 0.000 claims 2
- 206010052381 Primary adrenal insufficiency Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010039094 Rhinitis perennial Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 2
- 206010048709 Urosepsis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 206010003668 atrial tachycardia Diseases 0.000 claims 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 2
- 210000003710 cerebral cortex Anatomy 0.000 claims 2
- 208000036319 cervical spondylosis Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 2
- 201000010063 epididymitis Diseases 0.000 claims 2
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 210000003000 inclusion body Anatomy 0.000 claims 2
- 230000035987 intoxication Effects 0.000 claims 2
- 231100000566 intoxication Toxicity 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 150000003961 organosilicon compounds Chemical class 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 238000000718 qrs complex Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000020615 rectal carcinoma Diseases 0.000 claims 2
- 150000003873 salicylate salts Chemical class 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 208000005801 spondylosis Diseases 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000018672 Dilatation Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 102220492696 X-linked interleukin-1 receptor accessory protein-like 2_W34A_mutation Human genes 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 210000004375 bundle of his Anatomy 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 238000006757 chemical reactions by type Methods 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000003278 haem Chemical class 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000017376 neurovascular disease Diseases 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000023087 secondary adrenal insufficiency Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 230000028063 type III hypersensitivity Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000037997 venous disease Diseases 0.000 claims 1
- 201000005539 vernal conjunctivitis Diseases 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 8
- 239000005557 antagonist Substances 0.000 abstract description 5
- 230000011712 cell development Effects 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000000872 buffer Substances 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 241000282842 Lama glama Species 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- 239000002594 sorbent Substances 0.000 description 8
- 235000002198 Annona diversifolia Nutrition 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000012531 culture fluid Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100033461 Interleukin-17A Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 241000282553 Macaca Species 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 229960004540 secukinumab Drugs 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 3
- 102000039989 IL-17 family Human genes 0.000 description 3
- 108091069193 IL-17 family Proteins 0.000 description 3
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101000998143 Rattus norvegicus Interleukin-17A Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100033096 Interleukin-17D Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000718541 Tetragastris balsamifera Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940124829 interleukin-23 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 101100029932 Drosophila melanogaster lama gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 1
- 241000855538 Gallacea scleroderma Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 1
- 101710186068 Interleukin-17 receptor C Proteins 0.000 description 1
- 206010058142 Intestine transplant rejection Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000027093 acute inflammatory demyelinating polyradiculoneuropathy Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- QSHQKIURKJITMZ-BRPMRXRMSA-N cholane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC)[C@@]1(C)CC2 QSHQKIURKJITMZ-BRPMRXRMSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 102000044485 human IL17B Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 1
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014109854/10A RU2577228C2 (ru) | 2014-03-14 | 2014-03-14 | Анти-il-17-антитела, способ их получения и способ применения |
| PCT/RU2014/000808 WO2015137843A1 (ru) | 2014-03-14 | 2014-10-27 | Анти-il-17-антитела, способ их получения и способ применения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201600276A1 EA201600276A1 (ru) | 2017-04-28 |
| EA034854B1 true EA034854B1 (ru) | 2020-03-30 |
Family
ID=54072148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201600276A EA034854B1 (ru) | 2014-03-14 | 2014-10-27 | Анти-il-17-антитела, способ их получения и способ применения |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10442857B2 (enExample) |
| EP (1) | EP3130604A4 (enExample) |
| JP (1) | JP6647208B2 (enExample) |
| CN (1) | CN106795219B (enExample) |
| AR (1) | AR100573A1 (enExample) |
| BR (1) | BR112016010513A2 (enExample) |
| EA (1) | EA034854B1 (enExample) |
| MX (1) | MX2016005765A (enExample) |
| MY (1) | MY175878A (enExample) |
| RU (1) | RU2577228C2 (enExample) |
| TW (1) | TWI689518B (enExample) |
| WO (1) | WO2015137843A1 (enExample) |
| ZA (1) | ZA201602040B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2979219A1 (en) * | 2015-03-10 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind psma |
| CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
| EA201990673A1 (ru) * | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты |
| CN108359011B (zh) | 2017-07-21 | 2019-06-25 | 华博生物医药技术（上海）有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
| CN107522783B (zh) * | 2017-09-30 | 2020-07-07 | 华博生物医药技术（上海）有限公司 | 一种抗白介素17a的抗体、其制备方法和应用 |
| JP7445977B2 (ja) | 2018-01-29 | 2024-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒ２媒介性疾患及び障害の治療法 |
| CN108333373B (zh) * | 2018-03-28 | 2021-04-27 | 徐昉 | 血清炎症因子的应用 |
| CN110551215A (zh) * | 2018-05-30 | 2019-12-10 | 中山康方生物医药有限公司 | 抗白细胞介素-17a抗体、其药物组合物及其用途 |
| WO2020024931A1 (en) * | 2018-07-31 | 2020-02-06 | Shen Weiqun | Anti-il-17a antibodies and use thereof |
| CN111303283A (zh) * | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
| CN120025437A (zh) | 2019-01-31 | 2025-05-23 | 努玛治疗有限公司 | 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法 |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| RU2754760C2 (ru) * | 2019-04-02 | 2021-09-07 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция анти-il17a антитела и ее применение |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| CN116063493B (zh) * | 2022-07-22 | 2023-09-01 | 贵州省赛尔生物科技有限公司 | 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法 |
| AU2024240129A1 (en) | 2023-03-17 | 2025-10-09 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN120399065B (zh) * | 2023-12-21 | 2025-10-14 | 北京贝来药业有限公司 | 抗il-17a纳米抗体、药物组合物、方法及用途 |
| CN117820475B (zh) * | 2023-12-21 | 2024-10-29 | 北京贝来生物科技有限公司 | 针对il-17a的新型纳米抗体、药物、制备、方法及应用 |
| CN117843777B (zh) * | 2023-12-21 | 2024-08-27 | 北京贝来药业有限公司 | 用于炎性疾病治疗的新型纳米抗体及其产品和方法 |
| CN117820479B (zh) * | 2023-12-29 | 2025-03-07 | 北京贝来药业有限公司 | 抗il-17a的新型纳米抗体 |
| CN117843802B (zh) * | 2023-12-29 | 2024-09-06 | 北京贝来药业有限公司 | 串联抗体及其下游产品和应用 |
| CN118005785B (zh) * | 2023-12-29 | 2024-10-22 | 北京贝来药业有限公司 | 用于疾病治疗的串联纳米抗体 |
| CN117903304B (zh) * | 2023-12-29 | 2025-03-11 | 北京贝来药业有限公司 | 抗体的序列结构及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007149032A1 (en) * | 2006-06-23 | 2007-12-27 | Astrazeneca Ab | Antibody molecules for human il-17 |
| WO2008021156A2 (en) * | 2006-08-11 | 2008-02-21 | Schering Corporation | Antibodies to il-17a |
| US20130131319A1 (en) * | 2010-03-30 | 2013-05-23 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| EP2377887A1 (en) * | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| WO2007147019A2 (en) * | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| NZ607615A (en) * | 2010-08-05 | 2015-03-27 | Anaptysbio Inc | Antibodies directed against il-17 |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
-
2014
- 2014-03-14 RU RU2014109854/10A patent/RU2577228C2/ru active
- 2014-10-27 EA EA201600276A patent/EA034854B1/ru not_active IP Right Cessation
- 2014-10-27 BR BR112016010513A patent/BR112016010513A2/pt not_active Application Discontinuation
- 2014-10-27 EP EP14885545.5A patent/EP3130604A4/en not_active Withdrawn
- 2014-10-27 JP JP2016555518A patent/JP6647208B2/ja active Active
- 2014-10-27 MY MYPI2016702885A patent/MY175878A/en unknown
- 2014-10-27 CN CN201480027341.6A patent/CN106795219B/zh active Active
- 2014-10-27 MX MX2016005765A patent/MX2016005765A/es unknown
- 2014-10-27 WO PCT/RU2014/000808 patent/WO2015137843A1/ru not_active Ceased
-
2015
- 2015-03-11 TW TW104107806A patent/TWI689518B/zh not_active IP Right Cessation
- 2015-03-13 AR ARP150100768A patent/AR100573A1/es active IP Right Grant
-
2016
- 2016-03-29 ZA ZA2016/02040A patent/ZA201602040B/en unknown
- 2016-09-01 US US15/254,190 patent/US10442857B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007149032A1 (en) * | 2006-06-23 | 2007-12-27 | Astrazeneca Ab | Antibody molecules for human il-17 |
| WO2008021156A2 (en) * | 2006-08-11 | 2008-02-21 | Schering Corporation | Antibodies to il-17a |
| US20130131319A1 (en) * | 2010-03-30 | 2013-05-23 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
Non-Patent Citations (1)
| Title |
|---|
| CHEN GANG et al. "In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site." Protein engineering, 1999, vol. 12, no.4, pages 349-356 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3130604A1 (en) | 2017-02-15 |
| WO2015137843A1 (ru) | 2015-09-17 |
| MX2016005765A (es) | 2017-01-05 |
| TWI689518B (zh) | 2020-04-01 |
| CN106795219B (zh) | 2021-07-09 |
| RU2577228C2 (ru) | 2016-03-10 |
| US20170081401A1 (en) | 2017-03-23 |
| BR112016010513A2 (pt) | 2017-12-05 |
| TW201538524A (zh) | 2015-10-16 |
| JP6647208B2 (ja) | 2020-02-14 |
| ZA201602040B (en) | 2017-02-22 |
| JP2017508463A (ja) | 2017-03-30 |
| US10442857B2 (en) | 2019-10-15 |
| RU2014109854A (ru) | 2015-09-20 |
| MY175878A (en) | 2020-07-14 |
| EA201600276A1 (ru) | 2017-04-28 |
| EP3130604A4 (en) | 2017-11-01 |
| CN106795219A (zh) | 2017-05-31 |
| AR100573A1 (es) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2577228C2 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP7206303B2 (ja) | 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体 | |
| KR102751807B1 (ko) | Pd-1 항체 | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| JP7158376B2 (ja) | インターロイキン－６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント | |
| CN114846026A (zh) | 对人il-13和il-17具有结合特异性的多特异性抗体 | |
| HK40069078A (en) | Multi-specific antibody with binding specificity for human il-13 and il-17 | |
| OA19502A (en) | Antibody Or An Antigen-Binding Fragment Thereof Capable Of Binding To A Human Receptor Of Interleukin-6. | |
| OA19281A (en) | Trispecific antibodies against II-17A, II-17F and another proinflammatory molecule. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |